Delcath Systems Inc
NASDAQ:DCTH

Watchlist Manager
Delcath Systems Inc Logo
Delcath Systems Inc
NASDAQ:DCTH
Watchlist
Price: 11.23 USD -1.84%
Market Cap: 359m USD
Have any thoughts about
Delcath Systems Inc?
Write Note

Delcath Systems Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Delcath Systems Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Delcath Systems Inc
NASDAQ:DCTH
Total Receivables
$6.9m
CAGR 3-Years
363%
CAGR 5-Years
270%
CAGR 10-Years
46%
Becton Dickinson and Co
NYSE:BDX
Total Receivables
$3B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
10%
Boston Scientific Corp
NYSE:BSX
Total Receivables
$2.5B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
7%
Stryker Corp
NYSE:SYK
Total Receivables
$3.7B
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Total Receivables
$7.1B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Receivables
$1.2B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
16%
No Stocks Found

Delcath Systems Inc
Glance View

Market Cap
359m USD
Industry
Health Care

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

DCTH Intrinsic Value
12.95 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Delcath Systems Inc's Total Receivables?
Total Receivables
6.9m USD

Based on the financial report for Sep 30, 2024, Delcath Systems Inc's Total Receivables amounts to 6.9m USD.

What is Delcath Systems Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
46%

Over the last year, the Total Receivables growth was 3 207%. The average annual Total Receivables growth rates for Delcath Systems Inc have been 363% over the past three years , 270% over the past five years , and 46% over the past ten years .

Back to Top